Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Ms. Sanna Rydberg

Market Cap

110.68 Million SEK

Sector

Healthcare

Website

https://www.arcoma.se

Description

Arcoma AB develops, produces, and provides radiology solutions worldwide.

Read More

Overview

Value

17

Growth

18

Health

24

Management

55

Analyst Opinion

86

Total

40

All Scores Out Of 100

Best Features

  • Earnings growth has improved recently
  • Has a low level of debt
  • Liked by analysts
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Earnings are negative
  • There is a history of diluting shareholders
  • Poor overall financial health
  • No margin of safety at their current market price
  • Poor earnings and cashflow growth
  • Price-to-earnings ratio of 60.9 is higher than the market average (19.6x)

Market Peers

ARCOMA.ST

Key Figures

PE Ratio (TTM)

60.89

Margin Of Safety (DCF)

-65.29%

Revenue Growth (5 Year Average)

5.83%

Ratings Consensus

Strong Buy

Share Buybacks

-35.46%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

17

  • Estimated intrinsic-value of 2.94 SEK is lower than current price ( 8.48 SEK)
  • Price-to-earnings ratio of 60.9 is higher than the market average (19.6x)
  • Free-cashflow-yeild of 4.22% is worse than the market average (4.7%)
  • Margin-of-safety of -65.29% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 3.2 SEK

Current Price: 8.5 SEK

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

60.89x

Free Cashflow Yeild

4.22%

PE/Earnings Growth

N/A

Price/Book

2.52x

Growth

Growth Score

18

  • Earnings growth has improved this year
  • 5 Year Average Revenue growth of 5.83% is lower than the market average (10.97%)
  • Revenue growth has slowed this year
  • 5 Year Average Earnings growth of -12.28% is lower than the market average (14.48%)
  • 5 Year Average Free Cashflow growth of 3.71% is lower than the market average (12.35%)
  • Free Cashflow growth has slowed this year

Revenue Growth

5.83%

Earnings Growth

-12.28%

Cashflow Growth

3.71%

Health

Health Score

24

  • Has a low level of debt
  • Assets cover liabilities
  • Normal operation does not require debt to be sustainable
  • Debt repayments significantly impact cashflow

Altman Z Score

2.49

Piostroski Score

3.00

Debt/Equity

0.38x

Current Assets/Liabilities

1.31x

Free Cashflow/Total Debt

N/Ax

Debt/Capital

0.38x

Management

Management Score

55

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of 3.64% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of -7.05% is lower than the market average (15%)

Average Buybacks/Dilution

-35.46%

Recent Buybacks/Dilution

-58.47%

5 Year Price Volitility

26.45%

Return On Assets

-3.92%

Return On Capital Employed

3.64%

Return On Equity

-7.05%

Return On Free Cashflow

63.93%

Return On Investments

N/A

Analysts

Analyst Opinion

86

  • Ratings consensus is Strong Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Arcoma AB

Currency

SEK

Beta

1.041176

Vol Avg

16099

Ceo

Ms. Sanna Rydberg

Cik

Cusip

Exchange

Stockholm Stock Exchange

Full Time Employees

30

Industry

Medical Devices

Sector

Healthcare

Ipo Date

2014-11-14

Address

AnnavAegen 1

City

Växjö

State

Country

SE

Zip

352 46

Phone

46 4 70 70 69 00

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies